THE EXPERT BOARD'S ABSTRACT ON QUESTIONS OF THE SURVIVAL OF BIOLOGICAL AGENTS AND THE POSSIBILITY OF SWITCHING TO SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE

For citations:

THE EXPERT BOARD'S ABSTRACT ON QUESTIONS OF THE SURVIVAL OF BIOLOGICAL AGENTS AND THE POSSIBILITY OF SWITCHING TO SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE. Rheumatology Science and Practice. 2017;55(2):230-231. (In Russ.)